Arcutis Submits Supplemental NDA For ZORYVE Foam To The FDA For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Over
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) has submitted a supplemental New Drug Application (sNDA) to the FDA for ZORYVE foam, aimed at treating scalp and body psoriasis in individuals aged 12 and over. Clinical trials showed significant improvement and rapid itch reduction, with a favorable safety profile.
July 23, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics has submitted a supplemental NDA for ZORYVE foam to the FDA, targeting scalp and body psoriasis. Clinical trials indicate significant improvement and rapid itch reduction, with a favorable safety profile.
The submission of the sNDA for ZORYVE foam is a significant regulatory step that could lead to expanded market opportunities for Arcutis Biotherapeutics. Positive clinical trial results and a favorable safety profile enhance the likelihood of FDA approval, which could drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100